Rink T, Dembowski W, Schroth H J, Klinger K
Abteilung für Nuklearmedizin, Städtisches Klinikum, St. Vinzenz Krankenhaus, Hanau, Deutschland.
Nuklearmedizin. 2000 Aug;39(5):133-8.
AIM of this study is to evaluate new and controversially discussed indications for determining the thyroglobulin (Tg) level in different thyroid diseases to support routine diagnostics.
The following groups were included: 250 healthy subjects without goiter, 50 persons with diffuse goiter, 161 patients with multinodular goiter devoid of functional disorder (108 of them underwent surgery, in 17 cases carcinomas were detected), 60 hyperthyroid patients with autonomously functioning nodular goiter, 150 patients with Hashimoto's thyroiditis and 30 hyperthyroid patients with Graves' disease.
The upper limit of the normal range of the Tg level was calculated as 30 ng Tg/ml. The evaluation of the collective with diffuse goiter showed that the figure of the Tg level can be expected in a similar magnitude as the thyroid volume in milliliters. Nodular tissue led to far higher Tg values then presumed when considering the respective thyroid volume, with a rather high variance. A formula for a rough prediction of the Tg levels in nodular goiters is described. In ten out of 17 cases with thyroid carcinoma, the Tg was lower than estimated with thyroid and nodular volumes, but two patients showed a Tg exceeding 1000 ng/ml. The collective with functional autonomy had a significantly higher average Tg level than a matched euthyroid group being under suppressive levothyroxine substitution. However, due to the high variance of the Tg values, the autonomy could not consistently be predicted with the Tg level in individual cases. The patients with Hashimoto's thyroiditis showed slightly decreased Tg levels. In Graves' disease, a significantly higher average Tg level was observed compared with a matched group with diffuse goiter, but 47% of all Tg values were still in the normal range (< 30 ng/ml).
Elevated Tg levels indicate a high probability of thyroid diseases, such as malignancy, autonomy or Graves' disease. However, as low Tg concentrations cannot exclude the respective disorder, a routine Tg determination seems not to be justified in benign thyroid diseases.
本研究的目的是评估在不同甲状腺疾病中测定甲状腺球蛋白(Tg)水平的新的且存在争议的指征,以支持常规诊断。
纳入以下几组:250名无甲状腺肿的健康受试者、50名弥漫性甲状腺肿患者、161名无功能障碍的多结节性甲状腺肿患者(其中108例接受了手术,17例检测到癌症)、60例自主性功能性结节性甲状腺肿的甲亢患者、150例桥本甲状腺炎患者和30例格雷夫斯病的甲亢患者。
Tg水平正常范围的上限计算为30 ng Tg/ml。对弥漫性甲状腺肿群体的评估表明,Tg水平数值与以毫升为单位的甲状腺体积大小相似。结节组织导致的Tg值远高于考虑各自甲状腺体积时的推测值,且差异较大。描述了一个粗略预测结节性甲状腺肿中Tg水平的公式。在17例甲状腺癌病例中有10例,Tg低于根据甲状腺和结节体积估算的值,但有2例患者的Tg超过1000 ng/ml。具有功能自主性的群体的平均Tg水平明显高于接受左甲状腺素抑制替代治疗的匹配甲状腺功能正常组。然而,由于Tg值差异较大,在个别病例中无法通过Tg水平一致地预测自主性。桥本甲状腺炎患者的Tg水平略有下降。在格雷夫斯病中,与匹配的弥漫性甲状腺肿组相比,观察到平均Tg水平明显更高,但所有Tg值中有47%仍在正常范围内(<30 ng/ml)。
Tg水平升高表明甲状腺疾病(如恶性肿瘤、自主性或格雷夫斯病)的可能性很高。然而,由于低Tg浓度不能排除相应疾病,在良性甲状腺疾病中进行常规Tg测定似乎不合理。